There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.
BACKGROUND AND AIM Hepatoprotectants are routinely prescribed in China to prevent anti-tuberculosis drug-induced liver injury ( ATLI ) . However , their biological mechanisms have not yet been clearly demonstrated . This study aims to evaluate the preventive effects of Silybum marianum against drug-induced liver injury among tuberculosis patients and to provide clinical guidelines for tuberculosis management in China . METHODS A r and omized controlled trial was performed in Jiangsu , China . Tuberculosis patients were r and omly allocated to the experimental group ( anti-tuberculosis therapy plus S. marianum capsule ) or the control group ( anti-tuberculosis therapy plus vitamin C tablet ) . The primary outcomes were the occurrence of probable and possible ATLI , the peak aspartate aminotransferase/alanine aminotransferase ratio and the maximum altered alkaline phosphatase or gamma-glutamyl transferase . RESULTS The final analysis comprised 183 cases in the experiment group and 187 cases in the control group . The risk of developing probable ATLI was not significantly different between the two groups . During the follow-up period , 43.72 % of cases in the experiment group and 35.83 % of cases in the control group were determined to have possible ATLI ( relative risk = 1.23 , 95 % confidence interval : 0.94 - 1.54 ) . When using a more strict definition of possible ATLI , the adjusted relative risk ( 95 % confidence interval ) was 1.76 ( 1.14 - 2.56 ) . The risks of adverse drug reactions , prolonged treatment length , taking second-line tuberculosis drugs , and the clearance of tuberculosis bacteria were similar between the two groups . CONCLUSIONS No significant preventive effect of silymarin was found for either lowering the risk of liver injury or boosting the positive outcomes . Worse , we even found a potential risk of liver damage caused by the hepatoprotectant
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .